Thus, the loss of ALKBH5 function in these specific cancer types may represent a novel mechanism through which tumors evade immune recognition by lowering the expression of co-stimulatory molecules like CD70/CD80, thus suppressing T-cell activation, though this mechanism remains still hypothetical without any functional evidence. Here, CD80 is linked to cancer.